Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Endocrine causes of hypertension: literature review and practical approach

Hypertension Research volume 46, pages 2679–2692 (2023)Cite this article

Abstract

Hypertension (HTN) affects more than 30% of adults worldwide. It is the most frequent modifiable cardiovascular (CV) risk factor, and is responsible for more than 10 million death every year. Among patients with HTN, we usually distinguish secondary HTN, that is HTN due to an identified cause, and primary HTN, in which no underlying cause has been found. It is estimated that secondary hypertension represents between 5 and 15% of hypertensive patients [1]. Therefore, routine screening of patients for secondary HTN would be too costly and is not recommended. In addition to the presence of signs suggesting a specific secondary cause, screening is based on specific criteria. Identifying secondary HTN can be beneficial for patients in certain situations, because it may lead to specific treatments, and allow better control of blood pressure and sometimes even a cure. Besides, it is now known that secondary HTN are more associated with morbidity and mortality than primary HTN. The main causes of secondary HTN are endocrine and renovascular (mainly due to renal arteries abnormalities). The most frequent endocrine cause is primary aldosteronism, which diagnosis can lead to specific therapies. Pheochromocytoma and Cushing syndrome also are important causes, and can have serious complications. Other causes are less frequent and can be suspected on specific situations. In this article, we will describe the endocrine causes of HTN and discuss their treatments.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35:1245–54.

    Google Scholar 

  2. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317:165–82.

    PubMed  Google Scholar 

  4. de Freminville J-B, Amar L. How to explore an endocrine cause of hypertension. JCM. 2022;11:420.

    PubMed  PubMed Central  Google Scholar 

  5. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334–57.

    CAS  PubMed  Google Scholar 

  6. Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. Published Online First: 21 June 2023. https://doi.org/10.1097/HJH.0000000000003480.

  7. Braun LT, Vogel F, Reincke M. Long-term morbidity and mortality in patients with Cushing’s syndrome. J Neuroendocrinol. 2022;34:e13113.

    CAS  PubMed  Google Scholar 

  8. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41–50.

    CAS  PubMed  Google Scholar 

  9. Januszewicz A, Mulatero P, Dobrowolski P, Monticone S, Van der Niepen P, Sarafidis P, et al. Cardiac phenotypes in secondary hypertension. J Am Coll Cardiol. 2022;80:1480–97.

    Google Scholar 

  10. Conn JW. Plasma renin activity in primary aldosteronism: importance in differential diagnosis and in research of essential hypertension. JAMA. 1964;190:222–5.

    CAS  PubMed  Google Scholar 

  11. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism: a detectable cause of curable “Essential” hypertension. JAMA. 1965;193:200–6.

    CAS  PubMed  Google Scholar 

  12. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence That Primary Aldosteronism May Not Be Uncommon: 12% Incidence Among Antihypertensive Drug Trial Volunteers. Clin Exp Pharmacol Physiol. 1993;20:296–8.

    CAS  PubMed  Google Scholar 

  13. Anderson GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609–15.

    PubMed  Google Scholar 

  14. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharm Physiol. 1994;21:315–8.

    CAS  Google Scholar 

  15. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–2300.

    CAS  PubMed  Google Scholar 

  16. Plouin P-F, Amar L, Chatellier G, on behalf of the COMETE-Conn Study Group. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dialysis Transplant. 2004;19:774–7.

    Google Scholar 

  17. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies–a review of the current literature. Horm Metab Res. 2012;44:157–62.

    CAS  PubMed  Google Scholar 

  18. Buffolo F, Monticone S, Burrello J, Tetti M, Veglio F, Williams TA, et al. Is primary Aldosteronism still largely unrecognized? Horm Metab Res. 2017;49:908–14.

    CAS  PubMed  Google Scholar 

  19. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–20.

    PubMed  Google Scholar 

  20. Parasiliti-Caprino M, Lopez C, Prencipe N, Lucatello B, Settanni F, Giraudo G, et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens. 2020;38:1841–8.

    CAS  PubMed  Google Scholar 

  21. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10–20.

    PubMed  PubMed Central  Google Scholar 

  22. Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021;9:876–92.

    PubMed  Google Scholar 

  23. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921–6.

    CAS  PubMed  Google Scholar 

  24. Burrello J, Monticone S, Losano I, Cavaglià G, Buffolo F, Tetti M, et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension. 2020;75:1025–33.

    CAS  PubMed  Google Scholar 

  25. Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045–50.

    CAS  PubMed  Google Scholar 

  26. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond). 2007;113:267–78.

    CAS  PubMed  Google Scholar 

  27. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90:5070–6.

    CAS  PubMed  Google Scholar 

  28. Chang Y-Y, Liao C-W, Tsai C-H, Chen C-W, Pan C-T, Chen Z-W, et al. Left ventricular dysfunction in patients with primary aldosteronism: a propensity score-matching follow-up study with tissue doppler imaging. J Am Heart Assoc. 2019;8:e013263.

    PubMed  PubMed Central  Google Scholar 

  29. Hung C-S, Chou C-H, Liao C-W, Lin Y-T, Wu X-M, Chang Y-Y, et al. Aldosterone induces tissue inhibitor of Metalloproteinases-1 expression and further contributes to collagen accumulation: from clinical to bench studies. Hypertension. 2016;67:1309–20.

    CAS  PubMed  Google Scholar 

  30. Parksook WW, Williams GH. Aldosterone and cardiovascular diseases. Cardiovasc Res. 2022; cvac027.

  31. van der Heijden CDCC, Smeets EMM, Aarntzen EHJG, Noz MP, Monajemi H, Kersten S, et al. Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism. J Clin Endocrinol Metab. 2020;105:e1967–80.

    PubMed  Google Scholar 

  32. Demirkiran A, Everaars H, Elitok A, van de Ven PM, Smulders YM, Dreijerink KM, et al. Hypertension with primary aldosteronism is associated with increased carotid intima-media thickness and endothelial dysfunction. J Clin Hypertens (Greenwich). 2019;21:932–41.

    CAS  Google Scholar 

  33. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232–8.

    CAS  PubMed  Google Scholar 

  34. Monticone S, Sconfienza E, D’Ascenzo F, Buffolo F, Satoh F, Sechi LA, et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis. J Hypertens. 2020;38:3–12.

    CAS  PubMed  Google Scholar 

  35. Huby A-C, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. Circulation. 2015;132:2134–45.

    CAS  Google Scholar 

  36. Spyroglou A, Handgriff L, Müller L, Schwarzlmüller P, Parasiliti-Caprino M, Fuss CT, et al. The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex - a multicenter-study of 3566 Caucasian and Asian subjects. Eur J Endocrinol. 2022;187:361–72.

    CAS  PubMed  Google Scholar 

  37. Wolley MJ, Pimenta E, Calhoun D, Gordon RD, Cowley D, Stowasser M. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. J Hum Hypertens. 2017;31:561–7.

    CAS  Google Scholar 

  38. Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014;63:20–31.

    CAS  PubMed  Google Scholar 

  39. Savard S, Amar L, Plouin P-F, Steichen O. Cardiovascular complications associated with primary aldosteronism. Hypertension. 2013;62:331–6.

    CAS  Google Scholar 

  40. Milliez P, Girerd X, Plouin P-F, Blacher J, Safar ME, Mourad J-J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–8.

    CAS  PubMed  Google Scholar 

  41. Buffolo F, Tetti M, Mulatero P, Monticone S. Aldosterone as a mediator of cardiovascular damage. Hypertension. 2022;79:1899–911.

    CAS  PubMed  Google Scholar 

  42. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51–9.

    PubMed  Google Scholar 

  43. Inoue K, Goldwater D, Allison M, Seeman T, Kestenbaum BR, Watson KE. Serum aldosterone concentration, blood pressure, and coronary artery calcium: The multi-ethnic study of atherosclerosis. Hypertension. 2020;76:113–20.

    CAS  PubMed  Google Scholar 

  44. Amar L, Baguet JP, Bardet S, Chaffanjon P, Chamontin B, Douillard C, et al. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook. Ann d’Endocrinologie. 2016;77:179–86.

    Google Scholar 

  45. Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro M-C, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the european society of hypertension∗. J Hypertens. 2020;38:1919–28.

    CAS  Google Scholar 

  46. Seccia TM, Letizia C, Muiesan ML, Lerco S, Cesari M, Bisogni V, et al. Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. J Hypertens. 2020;38:332–9.

    CAS  Google Scholar 

  47. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161–5.

    CAS  PubMed  Google Scholar 

  48. Maiolino G, Rossitto G, Bisogni V, Cesari M, Seccia TM, Plebani M, et al. Quantitative value of aldosterone‐renin ratio for detection of aldosterone‐producing adenoma: the Aldosterone‐Renin Ratio for Primary Aldosteronism (AQUARR) Study. J Am Heart Assoc. 2017;6:e005574.

    PubMed  PubMed Central  Google Scholar 

  49. Reznik Y, Amar L, Tabarin A. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing. Ann Endocrinol (Paris). 2016;77:202–7.

    PubMed  Google Scholar 

  50. Baron S, Amar L, Faucon A-L, Blanchard A, Baffalie L, Faucard C, et al. Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration. J Hypertens. 2018; 36. https://doi.org/10.1097/HJH.0000000000001735.

  51. Funder JW. Primary aldosteronism. Hypertension. 2019;74:458–66.

    CAS  PubMed  Google Scholar 

  52. Douillard C, Houillier P, Nussberger J, Girerd X. SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps. Ann Endocrinol (Paris). 2016;77:192–201.

    PubMed  Google Scholar 

  53. Aldea ML, Barallat J, Martín MA, Rosas I, Pastor MC, Granada ML. Sodium interference in the determination of urinary aldosterone. Clin Biochem. 2016;49:295–7.

    CAS  PubMed  Google Scholar 

  54. Lin DC, Raizman JE, Holmes DT, Don-Wauchope AC, Yip PM. Evaluation of a chemiluminescent immunoassay for urinary aldosterone on the DiaSorin LIAISON automated platform against RIA and LC-MS/MS. Clin Chem Lab Med. 2017;55:e181–3.

    CAS  PubMed  Google Scholar 

  55. Alnazer RM, Veldhuizen GP, Kroon AA, de Leeuw PW. The effect of medication on the aldosterone-to-renin ratio. A critical review of the literature. J Clin Hypertens (Greenwich). 2021;23:208–14.

    PubMed  Google Scholar 

  56. Veldhuizen GP, Alnazer RM, de Leeuw PW, Kroon AA. The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof. Cardiovasc Drugs Ther. Published Online First: 13 September 2021. https://doi.org/10.1007/s10557-021-07262-3.

  57. Beeftink MMA, van der Sande NGC, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FLJ, et al. Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-to-Control Hypertension. Hypertension. 2017;69:927–32.

    CAS  PubMed  Google Scholar 

  58. Zennaro M-C, Boulkroun S, Fernandes-Rosa FL. Pathogenesis and treatment of primary aldosteronism. Nat Rev Endocrinol. 2020;16:578–89.

    CAS  PubMed  Google Scholar 

  59. Boulkroun S, Fernandes-Rosa FL, Zennaro M-C. Old and new genes in primary aldosteronism. Best Pr Res Clin Endocrinol Metab. 2020;34:101375.

    CAS  Google Scholar 

  60. Mulatero P, Sechi LA, Williams TA, Lenders JWM, Reincke M, Satoh F, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension ∗. J Hypertens. 2020;38:1929–36.

    CAS  Google Scholar 

  61. Bardet S, Chamontin B, Douillard C, Pagny J-Y, Hernigou A, Joffre F, et al. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis. Ann Endocrinol (Paris). 2016;77:208–13.

    PubMed  Google Scholar 

  62. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–916.

    CAS  PubMed  Google Scholar 

  63. Kempers MJE, Lenders JWM, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus ARMM, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151:329–37.

    PubMed  Google Scholar 

  64. Rossi GP, Crimì F, Rossitto G, Amar L, Azizi M, Riester A, et al. Feasibility of imaging-guided adrenalectomy in young patients with primary aldosteronism. Hypertension. 2022;79:187–95.

    CAS  PubMed  Google Scholar 

  65. Schloetelburg W, Ebert I, Petritsch B, Weng AM, Dischinger U, Kircher S, et al. Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. Eur J Endocrinol. 2021;186:183–93.

    PubMed  PubMed Central  Google Scholar 

  66. Gao Y, Ding J, Cui Y, Li T, Sun H, Zhao D, et al. Functional nodules in primary aldosteronism: identification of CXCR4 expression with 68Ga-pentixafor PET/CT. Eur Radio. 2023;33:996–1003.

    CAS  Google Scholar 

  67. Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension. 2018;71:317–25.

    CAS  PubMed  Google Scholar 

  68. Williams TA, Peitzsch M, Dietz AS, Dekkers T, Bidlingmaier M, Riester A, et al. Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. Hypertension. 2016;67:139–45.

    CAS  PubMed  Google Scholar 

  69. De Sousa K, Boulkroun S, Baron S, Nanba K, Wack M, Rainey WE, et al. Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma. Hypertension. 2020;75:1034–44.

    PubMed  Google Scholar 

  70. Le Floch E, Cosentino T, Larsen CK, Beuschlein F, Reincke M, Amar L, et al. Identification of risk loci for primary aldosteronism in genome-wide association studies. Nat Commun. 2022;13:5198.

    PubMed  PubMed Central  Google Scholar 

  71. Steichen O, Zinzindohoué F, Plouin P-F, Amar L. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm Metab Res. 2012;44:221–7.

    CAS  PubMed  Google Scholar 

  72. Williams TA, Gong S, Tsurutani Y, Tezuka Y, Thuzar M, Burrello J, et al. Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study. Lancet Diabetes Endocrinol. 2022;10:769–71.

    Google Scholar 

  73. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharm. 1999;48:756–60.

    CAS  Google Scholar 

  74. Parthasarathy HK, Ménard J, White WB, Young WF, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29:980–90.

    CAS  PubMed  Google Scholar 

  75. Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932–40.

    PubMed Central  Google Scholar 

  76. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes. N. Engl J Med. 2020;383:2219–29.

    CAS  PubMed  Google Scholar 

  77. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and Type 2 diabetes. N. Engl J Med. 2021;385:2252–63.

    CAS  Google Scholar 

  78. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474–84.

    CAS  PubMed  Google Scholar 

  79. Bogman K, Schwab D, Delporte M-L, Palermo G, Amrein K, Mohr S, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone Synthase (CYP11B2). Hypertension. 2017;69:189–96.

    CAS  Google Scholar 

  80. Azizi M, L Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol, dialysis, Transpl.: official publication of the European Dialysis and Transplant Association - European Renal Association 2013; 28. https://doi.org/10.1093/ndt/gfs388.

  81. Freeman MW, Halvorsen Y-D, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388:395–405.

    CAS  PubMed  Google Scholar 

  82. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. <B>Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan</B>. Hypertens Res. 2004;27:193–202.

    Google Scholar 

  83. Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665–75.

    Google Scholar 

  84. Amar L, Servais A, Gimenez-Roqueplo A-P, Zinzindohoue F, Chatellier G, Plouin P-F. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005;90:2110–6.

    CAS  PubMed  Google Scholar 

  85. Giavarini A, Chedid A, Bobrie G, Plouin P-F, Hagège A, Amar L. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart. 2013;99:1438–44.

    PubMed  Google Scholar 

  86. Zelinka T, Petrák O, Turková H, Holaj R, Štrauch B, Kršek M, et al. High Incidence of Cardiovascular Complications in Pheochromocytoma. Horm Metab Res. 2012;44:379–84.

    CAS  PubMed  Google Scholar 

  87. Dobrowolski P, Januszewicz A, Klisiewicz A, Gosk-Przybyłek M, Pęczkowska M, Kabat M, et al. Left ventricular structural and functional alterations in patients with pheochromocytoma/paraganglioma before and after surgery. JACC Cardiovasc Imaging. 2020;13:2498–509.

    PubMed  Google Scholar 

  88. Robertson V, Poli F, Hobson B, Saratzis A, Ross Naylor A. A systematic review and meta-analysis of the presentation and surgical management of patients with carotid body tumours. Eur J Vasc Endovasc Surg. 2019;57:477–86.

    PubMed  Google Scholar 

  89. Lenders JWM, Duh Q-Y, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.

    CAS  PubMed  Google Scholar 

  90. Eisenhofer G, Peitzsch M, Kaden D, Langton K, Mangelis A, Pamporaki C, et al. Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clin Chim Acta. 2019;490:46–54.

    CAS  PubMed  Google Scholar 

  91. Därr R, Kuhn M, Bode C, Bornstein SR, Pacak K, Lenders JWM, et al. Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine. 2017;56:495–503.

    PubMed  PubMed Central  Google Scholar 

  92. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo A-P, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pr Endocrinol Metab. 2007;3:92–102.

    Google Scholar 

  93. Boyle JG, Davidson DF, Perry CG, Connell JMC. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic Acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. J Clin Endocrinol Metab. 2007;92:4602–8.

    CAS  PubMed  Google Scholar 

  94. Pamporaki C, Prejbisz A, Małecki R, Pistrosch F, Peitzsch M, Bishoff S, et al. Optimized procedures for testing plasma metanephrines in patients on hemodialysis. Sci Rep. 2021;11:14706.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Därr R, Pamporaki C, Peitzsch M, Miehle K, Prejbisz A, Peczkowska M, et al. Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf). 2014;80:478–86.

    PubMed  Google Scholar 

  96. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.

    CAS  PubMed  Google Scholar 

  97. Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38:1443–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Plouin P-F, Gimenez-Roqueplo A-P. Pheochromocytomas and secreting paragangliomas. Orphanet J Rare Dis. 2006;1:49.

    PubMed  PubMed Central  Google Scholar 

  99. Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  100. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112–37.

    PubMed  PubMed Central  Google Scholar 

  101. Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104:700–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Amar L, Lussey-Lepoutre C, Lenders JWM, Djadi-Prat J, Plouin P-F, Steichen O. Management of endocrine disease: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175:R135–45.

    CAS  PubMed  Google Scholar 

  103. Favier J, Amar L, Gimenez-Roqueplo A-P. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11:101–11.

    CAS  PubMed  Google Scholar 

  104. Burnichon N, Buffet A, Gimenez-Roqueplo A-P. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine. Curr Opin Oncol. 2016;28:5–10.

    CAS  PubMed  Google Scholar 

  105. Tian J, Bao Z, Yuan Y, Fang D, Zhan Y, Wang T, et al. The duration of preoperative administration of single α-Receptor Blocker Phenoxybenzamine before Adrenalectomy for Pheochromocytoma: 18 Years of Clinical Experience from Nationwide High-Volume Center. Biomed Res Int. 2019;2019:2613137.

    PubMed  PubMed Central  Google Scholar 

  106. Castinetti F, De Freminville JB, Guerin C, Cornu E, Sarlon G, Amar L. Controversies about the systematic preoperative pharmacological treatment before pheochromocytoma or paraganglioma surgery. Eur J Endocrinol. 2022;186:D17–24.

    CAS  PubMed  Google Scholar 

  107. Gruber LM, Jasim S, Ducharme-Smith A, Weingarten T, Young WF, Bancos I. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. 2021;106:e2393–2401.

    PubMed  PubMed Central  Google Scholar 

  108. Wengander S, Trimpou P, Papakokkinou E, Ragnarsson O. The incidence of endogenous Cushing’s syndrome in the modern era. Clin Endocrinol. 2019;91:263–70.

    CAS  Google Scholar 

  109. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BMK, Colao A. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4:611–29.

    CAS  PubMed  Google Scholar 

  110. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JOL. Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012;23:278–82.

    CAS  Google Scholar 

  111. Deutschbein T, Reimondo G, Dalmazi GD, Bancos I, Patrova J, Vassiliadi DA, et al. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol. 2022;10:499–508.

    CAS  PubMed  PubMed Central  Google Scholar 

  112. Cicala MV, Mantero F. Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92:44–9.

    CAS  PubMed  Google Scholar 

  113. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens. 2004;13:451–8.

    CAS  PubMed  Google Scholar 

  114. Lugat A, Lasolle H, François M, Benhenda N, Bricaire L, Cornu E, et al. Pneumocystis pneumonia in patients with Cushing’s syndrome: a French multicenter retrospective study. Ann Endocrinol (Paris). 2022;S0003-4266:00836–8.

    Google Scholar 

  115. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MTB, Fliers E, et al. Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab. 2009;94:2743–50.

    PubMed  Google Scholar 

  116. Tabarin A, Assié G, Barat P, Bonnet F, Bonneville JF, Borson-Chazot F, et al. Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing’s syndrome. Ann d’Endocrinologie. 2022;83:119–41.

    Google Scholar 

  117. Nieman, Biller BMK LK, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–40.

    CAS  PubMed Central  Google Scholar 

  118. Braun LT, Vogel F, Zopp S, Marchant Seiter T, Rubinstein G, Berr CM, et al. Whom should we screen for Cushing syndrome? The Endocrine Society Practice Guideline Recommendations 2008 revisited. J Clin Endocrinol Metab. 2022;107:e3723–30.

    PubMed Central  Google Scholar 

  119. Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9:847–75.

    PubMed Central  Google Scholar 

  120. Galm BP, Qiao N, Klibanski A, Biller BMK, Tritos NA. Accuracy of laboratory tests for the diagnosis of Cushing syndrome. J Clin Endocrinol Metab. 2020;105:2081–94.

    Google Scholar 

  121. Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, et al. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165:383–92.

    CAS  PubMed  Google Scholar 

  122. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet. 2006;367:1605–17.

    CAS  Google Scholar 

  123. Steffensen C, Bak AM, Rubeck KZ, Jørgensen JOL. Epidemiology of Cushing’s syndrome. NEN. 2010;92:1–5.

    CAS  Google Scholar 

  124. Aresta C, Favero V, Morelli V, Giovanelli L, Parazzoli C, Falchetti A, et al. Cardiovascular complications of mild autonomous cortisol secretion. Best Pract Res Clin Endocrinol Metab. 2021;35:101494.

    CAS  Google Scholar 

  125. Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab. 2021;35:101521.

    CAS  PubMed  Google Scholar 

  126. Rubinstein G, Osswald A, Braun LT, Vogel F, Kroiss M, Pilz S, et al. The role of adrenal venous sampling (AVS) in primary bilateral macronodular adrenocortical hyperplasia (PBMAH): a study of 16 patients. Endocrine. 2022;76:434–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  127. Bertherat J, Bourdeau I, Bouys L, Chasseloup F, Kamenický P, Lacroix A. Clinical, pathophysiologic, genetic, and therapeutic progress in primary bilateral macronodular adrenal hyperplasia. Endocr Rev. 2023;44:567–628.

    PubMed  Google Scholar 

  128. Theodoropoulou M, Reincke M. Genetics of Cushing’s disease: from the lab to clinical practice. Pituitary. 2022;25:689–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. Fleseriu M, Biller BMK. Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary. 2022;25:795–809.

    CAS  PubMed  PubMed Central  Google Scholar 

  130. Brue T, Rahabi H, Barry A, Barlier A, Bertherat J, Borson-Chazot F, et al. Position statement on the diagnosis and management of acromegaly: the French National Diagnosis and Treatment Protocol (NDTP). Annales d’Endocrinologie 2023;S0003426623006868.

  131. Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nat Rev Dis Prim. 2019;5:20.

    PubMed  Google Scholar 

  132. Maione L, Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019;33:101264.

    PubMed  Google Scholar 

  133. Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. 2020;105:e937–46.

    Google Scholar 

  134. González B, Vargas G, De Los Monteros ALE, Mendoza V, Mercado M. Persistence of diabetes and hypertension after multimodal treatment of acromegaly. J Clin Endocrinol Metab. 2018;103:2369–75.

    PubMed  Google Scholar 

  135. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667–74.

    CAS  PubMed  Google Scholar 

  136. Garby L, Caron P, Claustrat F, Chanson P, Tabarin A, Rohmer V, et al. Clinical Characteristics and Outcome of Acromegaly Induced by Ectopic Secretion of Growth Hormone-Releasing Hormone (GHRH): A French Nationwide Series of 21 Cases. J Clin Endocrinol Metab. 2012;97:2093–104.

    CAS  PubMed  Google Scholar 

  137. Gadelha MR, Kasuki L, Korbonits M. The genetic background of acromegaly. Pituitary. 2017;20:10–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  138. Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020;21:667–78.

    PubMed  PubMed Central  Google Scholar 

  139. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet. 2017;390:2194–210.

    CAS  PubMed  Google Scholar 

  140. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. A summary of the endocrine society clinical practice guidelines on congenital adrenal hyperplasia due to Steroid 21-Hydroxylase deficiency. Int J Pediatr Endocrinol. 2010;2010:494173.

    PubMed  PubMed Central  Google Scholar 

  141. Nicolaides NC, Roberts ML, Kino T, Braatvedt G, Hurt DE, Katsantoni E, et al. A Novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL Motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities. J Clin Endocrinol Metab. 2014;99:E902–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  142. Vitellius G, Lombes M. Genetics in endocrinology: glucocorticoid resistance syndrome. Eur J Endocrinol. 2020;182:R15–27.

    CAS  Google Scholar 

  143. Jeunemaitre X, Bassilana F, Persu A, Dumont C, Champigny G, Lazdunski M, et al. Genotype-phenotype analysis of a newly discovered family with Liddle’s syndrome. J Hypertens. 1997;15:1091–1100.

    CAS  PubMed  Google Scholar 

  144. Garovic VD, Hilliard AA, Turner ST. Monogenic forms of low-renin hypertension. Nat Clin Pr Nephrol. 2006;2:624–30.

    CAS  Google Scholar 

  145. Young WF Jr, Calhoun DA, Lenders JWM, Stowasser M, Textor SC. Screening for endocrine hypertension: an endocrine society scientific statement. Endocr Rev. 2017;38:103–22.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Unit, AP-HP, Hôpital Européen Georges Pompidou, F-75015, Paris, France

    Jean-Baptiste de Freminville, Laurence Amar, Michel Azizi & Julien Mallart-Riancho

  2. Université Paris Cité,, F-75015, Paris, France

    Jean-Baptiste de Freminville, Laurence Amar, Michel Azizi & Julien Mallart-Riancho

Authors
  1. Jean-Baptiste de Freminville
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence Amar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Azizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julien Mallart-Riancho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Baptiste de Freminville.

Ethics declarations

Conflict of interest

The author declares no competing interests

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Freminville, JB., Amar, L., Azizi, M. et al. Endocrine causes of hypertension: literature review and practical approach. Hypertens Res 46, 2679–2692 (2023). https://doi.org/10.1038/s41440-023-01461-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-023-01461-1

Keywords

Search

Advanced search

Quick links